FDA Approves Zinplava to Prevent C. diff Infection Recurrence

The injection is approved to reduce the recurrence of Clostridium difficile infection for high risk patients
The injection is approved to reduce the recurrence of Clostridium difficile infection for high risk patients

Merck announced that the Food and Drug Administration (FDA) has approved Zinplava (bezlotoxumab) Injection to reduce the recurrence of Clostridium difficile infection (CDI) in patients aged 18 years or older who are receiving antibacterial treatment of CDI and are at high risk for CDI recurrence. 

In June 2016, the FDA's Antimicrobial Drugs Advisory Committee voted 10-5 to recommend the approval of Zinplava based on the presentation of substantial evidence to support its safety and efficacy in patients aged ≥18 years. It was also granted Priority Review for its Biologics License Application (BLA) in January 2016.

Zinplava is a human monoclonal IgG1/kappa antibody that binds to C. difficile toxin B and neutralizes its effects. It inhibits the binding of toxin B and prevents its effects on mammalian cells; it does not bind to C. difficile toxin A. It is not an antibacterial drug and should only be used in conjunction with antibacterial treatment of CDI. 

Related Articles

The safety and efficacy of Zinplava were investigated in two randomized, double-blind, placebo-controlled, multicenter, Phase 3 trials (Trial 1 and Trial 2) in patients receiving Standard of Care antibacterial drugs for treatment of CDI (metronidazole, vancomycin, or fidaxomicin).  Sustained clinical response was defined as clinical cure of the presenting CDI episode and no CDI recurrence through 12 weeks after infusion. In Trial 1, 60.1% of patients in the Zinplava arm had sustained clinical response compared to 55.2% in the placebo arm. In Trial 2, 66.8% of Zinplava-treated patients had sustained clinical response versus 52.1% in the placebo group.

Heart failure was reported more commonly in the two Phase 3 clinical trials in Zinplava-treated patients compared to placebo-treated patients. These adverse reactions occurred primarily in patients with underlying congestive heart failure (CHF). In patients with a history of CHF, Zinplava should be reserved for use when the benefit outweighs the risk.

Zinplava Injection will be available as a 25mg/mL (1,000mg/40mL) strength preservative-free solution in single-dose vials. It is anticipated to launch in the first quarter of 2017.

For more information call (877) 888-4231 or visit Zinplava.com

Loading links....